Winning Stock Forecast: Arrowhead Pharmaceuticals (NASDAQ: ARWR) Returns up to 321.18% in 1 Year
Source https://it.depositphotos.com/3798928/stock-photo-tablets-medicines.html
Since the beginning of 2018 Arrowhead Pharmaceuticals showed growth catalysts for this year. First, according to the quarterly report for the period ended December 31, 2017, on September 28, 2016 the Company entered into a collaboration agreement with Amgen Inc. The Company received a worldwide license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target, that makes Amgen wholly responsible for clinical development and commercialization of this technology. Moreover, the
